# Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

> **NCT03366766** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 14 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Carcinoma
- Stage I Non-Small Cell Lung Cancer
- Stage IA Non-Small Cell Lung Carcinoma
- Stage IB Non-Small Cell Lung Carcinoma
- Stage II Non-Small Cell Lung Cancer
- Stage IIA Non-Small Cell Lung Carcinoma
- Stage IIB Non-Small Cell Lung Carcinoma
- Stage IIIA Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed Disodium
- **DRUG:** Gemcitabine Hydrochloride

## Key facts

- **NCT ID:** NCT03366766
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-20
- **Primary completion:** 2020-12-06
- **Final completion:** 2023-02-08
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** slow accrual and lack of additional funding
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366766, "Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03366766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*